The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
新一代口服选择性雌激素受体降解剂卡米泽司群 (AZD9833) 可抑制 ER+ 乳腺癌的生长并克服内分泌和 CDK4/6 抑制剂耐药性。
期刊:Cancer Research
影响因子:12.5
doi:10.1158/0008-5472.CAN-23-0694
Mandy Lawson # ,Natalie Cureton # ,Susana Ros # ,Azadeh Cheraghchi-Bashi ,Jelena Urosevic ,Sophie D'Arcy ,Oona Delpuech ,Michelle DuPont ,David I Fisher ,Eric T Gangl ,Hilary Lewis ,Dawn Trueman ,Neha Wali ,Stuart C Williamson ,Jennifer Moss ,Elodie Montaudon ,Heloise Derrien ,Elisabetta Marangoni ,Ricardo J Miragaia ,Sladjana Gagrica ,Pablo Morentin-Gutierrez ,Thomas A Moss ,Gareth Maglennon ,Daniel Sutton ,Radoslaw Polanski ,Alan Rosen ,Jonathan Cairns ,Pei Zhang ,Mònica Sánchez-Guixé ,Violeta Serra ,Susan E Critchlow ,James S Scott ,Justin P O Lindemann ,Simon T Barry ,Teresa Klinowska ,Christopher J Morrow ,Larissa S Carnevalli
